Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–17. https://doi.org/10.1016/S0140-6736(22)02420-5.

Article  PubMed  CAS  Google Scholar 

Loibl S, Holtschmidt J. Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some? Lancet. 2023;402(10411):1394–5. https://doi.org/10.1016/S0140-6736(23)01783-X.

Article  PubMed  CAS  Google Scholar 

Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–29. https://doi.org/10.1016/S0140-6736(16)32417-5.

Article  PubMed  CAS  Google Scholar 

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–69. https://doi.org/10.1016/S0140-6736(20)32381-3.

Article  PubMed  CAS  Google Scholar 

Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022.

Article  PubMed  Google Scholar 

Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002.

Article  PubMed  CAS  Google Scholar 

Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, Sakai Y. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer. 2017;20(3):416–27. https://doi.org/10.1007/s10120-016-0627-z.

Article  PubMed  CAS  Google Scholar 

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27. https://doi.org/10.1016/j.ccr.2004.06.022.

Article  PubMed  CAS  Google Scholar 

Gschwantler-Kaulich D, Tan YY, Fuchs EM, Hudelist G, Köstler WJ, Reiner A, Leser C, Salama M, Attems J, Deutschmann C, Zielinski CC, Singer CF. PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer. PLoS ONE. 2017;12(3): e0172911. https://doi.org/10.1371/journal.pone.0172911.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang Z, Liu N. PIWI interacting RNA-13643 contributes to papillary thyroid cancer development through acting as a novel oncogene by facilitating PRMT1 mediated GLI1 methylation. Biochim Biophys Acta Gen Subj. 2023;1867(11): 130453. https://doi.org/10.1016/j.bbagen.2023.

Article  PubMed  CAS  Google Scholar 

Yang Y, Zhou Z, Wang L, Gao P, Wu Z. G9a and DNMT1 inhibition modulates CDKN1A promoter methylation and the cell cycle leading to improvement in kidney fibrosis. Biochim Biophys Acta Gen Subj. 2023;1867(9): 130417. https://doi.org/10.1016/j.bbagen.2023.130417.

Article  PubMed  CAS  Google Scholar 

Liang WW, Lu RJ, Jayasinghe RG, Foltz SM, Porta-Pardo E, Geffen Y, Wendl MC, Lazcano R, Kolodziejczak I, Song Y, Govindan A, Demicco EG, Li X, Li Y, Sethuraman S, Payne SH, Fenyö D, Rodriguez H, Wiznerowicz M, Shen H, Mani DR, Rodland KD, Lazar AJ, Robles AI, Ding L, Clinical Proteomic Tumor Analysis Consortium. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 2023;41(9):1567-1585.e7. https://doi.org/10.1016/j.ccell.2023.07.013.

Article  PubMed  CAS  Google Scholar 

Tibben BM, Rothbart SB. Mechanisms of DNA methylation regulatory function and crosstalk with histone lysine methylation. J Mol Biol. 2024;436(7): 168394. https://doi.org/10.1016/j.jmb.2023.168394.

Article  PubMed  CAS  Google Scholar 

Huang Y, Zhao Z, Yi G, Zhang M. Importance of DNA nanotechnology for DNA methyltransferases in biosensing assays. J Mater Chem B. 2024;12(17):4063–79. https://doi.org/10.1039/d3tb02947f.

Article  PubMed  CAS  Google Scholar 

Mohammed FH, Cemic F, Hemberger J, Giri S. Biological skin regeneration using epigenetic targets. Drug Discov Today. 2023;28(4): 103495. https://doi.org/10.1016/j.drudis.2023.103495.

Article  PubMed  CAS  Google Scholar 

Wong KK. DNMT1: a key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198–213. https://doi.org/10.1016/j.semcancer.2020.05.010.

Article  PubMed  CAS  Google Scholar 

Qureshi MZ, Sabitaliyevich UY, Rabandiyarov M, Arystanbekuly AT. Role of DNA methyltransferases (DNMTs) in metastasis. Cell Mol Biol. 2022;68(1):226–36.

Article  PubMed  Google Scholar 

Kraya AA, Maxwell KN, Eiva MA, Wubbenhorst B, Pluta J, Feldman M, Nayak A, Powell DJ Jr, Domchek SM, Vonderheide RH, Nathanson KL. PTEN loss and BRCA1 promoter hypermethylation negatively predict for immunogenicity in BRCA-deficient ovarian cancer. JCO Precis Oncol. 2022;6: e2100159. https://doi.org/10.1200/PO.21.00159.

Article  PubMed  PubMed Central  Google Scholar 

Park HS, Kim JH, Cho MY, Chung KY, Roh MR. PTEN promoter hypermethylation is associated with breslow thickness in acral melanoma on the heel, forefoot, and hallux. Ann Dermatol. 2021;33(1):18–25. https://doi.org/10.5021/ad.2021.33.1.18.

Article  PubMed  CAS  Google Scholar 

Wong KK. DNMT1: a key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198–213. https://doi.org/10.1016/j.semcancer.2020.05.010.

Article  PubMed  CAS  Google Scholar 

Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y, Jiang G, Lu M, Zhang Z, Yin J, Zeng S, Chen X, Deng M, Jia X, Gu Y, Chen D, Zheng G, He Z. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 2020;27(3):966–83. https://doi.org/10.1038/s41418-019-0389-3.

Article  PubMed  CAS  Google Scholar 

Wong KK, Lawrie CH, Green TM. Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia. Biomark Insights. 2019;8(14):1177271919846454. https://doi.org/10.1177/1177271919846454.

Article  Google Scholar 

Yan L, Geng Q, Cao Z, Liu B, Li L, Lu P, Lin L, Wei L, Tan Y, He X, Li L, Zhao N, Lu C. Insights into DNMT1 and programmed cell death in diseases. Biomed Pharmacother. 2023;168: 115753. https://doi.org/10.1016/j.biopha.2023.115753.

Article  PubMed  CAS  Google Scholar 

Zhang X, Xia F, Zhang X, Blumenthal RM, Cheng X. C2H2 zinc finger transcription factors associated with hemoglobinopathies. J Mol Biol. 2024;436(7): 168343. https://doi.org/10.1016/j.jmb.2023.168343.

Article  PubMed  CAS  Google Scholar 

Zheng X, Lian Y, Zhou J, Zhou Q, Zhu Y, Tang C, Zhang P, Zhao X. Placental ischemia disrupts DNA methylation patterns in distal regulatory regions in rats. Life Sci. 2023;15(321): 121623. https://doi.org/10.1016/j.lfs.2023.121623.

Article  CAS  Google Scholar 

Gao Q, Chen F, Zhang L, Wei A, Wang Y, Wu Z, Cao W. Inhibition of DNA methyltransferase aberrations reinstates antioxidant aging suppressors and ameliorates renal aging. Aging Cell. 2022;21(1): e13526. https://doi.org/10.1111/acel.13526.

Article  PubMed  CAS  Google Scholar 

Gu P, Huang W, Lu W, Shu P. Regulation of the RB1 Gene through DNMT1 by SGI-1027 and its impact on the growth and metastasis of gastric cancer cells. Discov Med. 2024;36(184):923–35. https://doi.org/10.24976/Discov.Med.202436184.86.

Article  PubMed